Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients

被引：0
|
作者：
Ninh M. La-Beck
Beth A. Zamboni
Alberto Gabizon
Hilary Schmeeda
Michael Amantea
Paola A. Gehrig
William C. Zamboni
机构：
[1] University of North Carolina at Chapel Hill,UNC Eshelman School of Pharmacy
[2] Texas Tech University Health Sciences Center,Center for Immunotherapeutic Research and Department of Pharmacy Practice, School of Pharmacy
[3] Carlow University,Department of Mathematics
[4] Shaare Zedek Medical Center and Hebrew University-School of Medicine,Department of Oncology
[5] Pfizer,Department of Clinical Pharmacology
[6] Inc.,Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, UNC School of Medicine
[7] University of North Carolina at Chapel Hill,Molecular Therapeutics, Lineberger Comprehensive Cancer Center
[8] University of North Carolina at Chapel Hill,Institute for Pharmacogenomics and Individualized Therapy
[9] University of North Carolina at Chapel Hill,Carolina Center of Cancer Nanotechnology Excellence
[10] University of North Carolina at Chapel Hill,Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy
[11] University of North Carolina at Chapel Hill,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2012年 / 69卷
关键词：
Doxil; Liposomal; Pharmacokinetics; Variability; Monocytes; Reticuloendothelial system; Doxorubicin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：43 / 50
页数：7
相关论文
共 50 条
  • [21] Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma
    Lyass, O
    Uziely, B
    Ben-Yosef, R
    Tzemach, D
    Heshing, NI
    Lotem, M
    Brufman, G
    Gabizon, A
    CANCER, 2000, 89 (05) : 1037 - 1047
  • [22] Paclitaxel and pegylated liposomal doxorubicin association: effects of different administration intervals on the pharmacokinetics
    Airoldi, M.
    Cattel, L.
    Milla, P.
    Cerutti, E.
    Pedani, F.
    Crova, A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 330 - 331
  • [23] The hepatic pharmacokinetics of doxorubicin and liposomal doxorubicin
    Hilmer, SN
    Cogger, VC
    Muller, M
    Le Couteur, DG
    DRUG METABOLISM AND DISPOSITION, 2004, 32 (08) : 794 - 799
  • [24] Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
    Rao N. V. S. Mamidi
    Steve Weng
    Susan Stellar
    Charles Wang
    Ning Yu
    Tony Huang
    Alfred P. Tonelli
    Michael F. Kelley
    Anthony Angiuoli
    Man-Cheong Fung
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 1173 - 1184
  • [25] Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
    Mamidi, Rao N. V. S.
    Weng, Steve
    Stellar, Susan
    Wang, Charles
    Yu, Ning
    Huang, Tony
    Tonelli, Alfred P.
    Kelley, Michael F.
    Angiuoli, Anthony
    Fung, Man-Cheong
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (06) : 1173 - 1184
  • [26] Pegylated Liposomal Doxorubicin in Salvage Chemotherapy for Multiple Myeloma Patients
    Romano, Alessandra
    Uccello, Giuseppina
    Spina, Paolo
    Cunsolo, Rosario
    Vetro, Calogero
    Di Raimondo, Francesco
    CURRENT CANCER THERAPY REVIEWS, 2013, 9 (01) : 1 - 7
  • [27] Intrahepatic pegylated liposomal doxorubicin (PLD) in patients with liver malignancies
    Granetto, C.
    Fea, E.
    Colantonio, I
    Di Costanzo, G.
    Garrone, O.
    Gasco, M.
    Occelli, M.
    Heouaine, A.
    Numico, G.
    Merlano, M.
    ANNALS OF ONCOLOGY, 2006, 17 : 32 - 32
  • [28] Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors
    Villanucci, Alessandro
    Tavella, Ketty
    Vannini, Laura
    Rossi, Virginia
    Nobili, Stefania
    Amunni, Gianni
    Mazzei, Teresita
    Mini, Enrico
    MOLECULAR AND CLINICAL ONCOLOGY, 2018, 9 (06) : 635 - 639
  • [29] Pembrolizumab plus pegylated liposomal Doxorubicin for Patients with Ovarian Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2021, 81 (01) : 19 - 20
  • [30] Pegylated liposomal doxorubicin intertriginous eruption
    Monteagudo, B.
    Afonso-Afonso, F. J.
    Cabanillas, M.
    Used-Aznar, M. M.
    ACTAS DERMO-SIFILIOGRAFICAS, 2009, 100 (03): : 241 - 243
12345